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BACKGROUND: The UK National Institute for Health and Clinical Excellence (NICE) guidance recommends conservative management
of men with ‘low-risk’ localised prostate cancer, monitoring the disease using prostate-specific antigen (PSA) kinetics and re-biopsy.
However, there is little evidence of the changes in PSA level that should alert to the need for clinical re-assessment.
METHODS: This study compares the alerts resulting from PSA kinetics and a novel longitudinal reference range approach, which
incorporates age-related changes, during the monitoring of 408 men with localised prostate cancer. Men were monitored by regular
PSA tests over a mean of 2.9 years, recording when a man’s PSA doubling time fell below 2 years, PSA velocity exceeded 2ngml
–1
per year, or when his upper 10% reference range was exceeded.
RESULTS: Prostate-specific antigen doubling time and PSA velocity alerted a high proportion of men initially but became unresponsive
to changes with successive tests. Calculating doubling time using recent PSA measurements reduced the decline in response. The
reference range method maintained responsiveness to changes in PSA level throughout the monitoring.
CONCLUSION: The increasing unresponsiveness of PSA kinetics is a consequence of the underlying regression model. Novel methods
are needed for evaluation in cohorts currently being managed by monitoring. Meanwhile, the NICE guidance should be cautious.
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The UK National Institute for Health and Clinical Excellence
(NICE) currently recommends that active surveillance is the
management strategy of choice for men with localised prostate
cancer and a low risk of disease progression; prostate-specific
antigen (PSA) o10ngml
–1 and Gleason score of p6 and clinical
stage T1-T2a, the so-called ‘low-risk’ prostate cancer (National
Institute for Health and Clinical Excellence, 2008). For men with an
intermediate risk of disease progression (PSA 10–20ngml
–1 or
Gleason score 7 or clinical stage T2b-T2c), NICE recommend that
active surveillance should be considered alongside more radical
treatment options (National Institute for Health and Clinical
Excellence, 2008).
These recommendations are based on expert opinion. They are
appealing because most men with localised prostate cancer
detected by PSA testing have slow-growing disease, with death
due to other causes often intervening before the disease becomes
life threatening (Albertsen et al, 2005). Although radical treatment
is potentially curative for localised disease, there is a significant
risk of serious side effects (Frankel et al, 2003). Consequently, for
men at low risk of disease progression at diagnosis, monitoring
strategies (commonly referred to as ‘active surveillance’, ‘active
monitoring’ or ‘expectant management’) potentially offer a good
balance of risk and benefit, as radical treatment is only undertaken
in low-risk men if they subsequently show signs of disease
progression (Albertsen et al, 2005; Klotz, 2007).
Only the Scandinavian Prostate Cancer Group Study Number 4
(SPCG-4 study) provides relevant trial evidence in this clinical
area, and supports a survival advantage for surgery over ‘watchful
waiting’ (Bill-Axelson et al, 2005). However, watchful waiting
does not involve the close monitoring characteristic of modern
approaches to conservative management, and the men in SPCG-4
had localised prostate cancer that was clinically detected before
PSA testing became common. Consequently these men were older
(54% aged 66 years or more) and had a higher Gleason score (33%
Gleason score 7 or more) than is typical for men diagnosed after
PSA testing (Bill-Axelson et al, 2005). Studies of monitoring in
PSA-era cohorts are ongoing, but it will be some time before they
report clinical outcomes (Donovan et al, 2003; Hardie et al, 2005;
Klotz, 2007; van den Bergh et al, 2007). In the meantime, the NICE
recommendations are not supported by empirical evidence, but are
underpinned by an attempt to apply the SPCG-4 results to a model
of a contemporary cohort (Parker et al, 2006).
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sSuccessful monitoring requires the identification of men whose
disease will soon progress, although still allowing for timely,
potentially curative treatment. Concurrently, men with indolent
disease should not be alerted to the need for clinical reassessment
unnecessarily, to avoid invasive investigations and overtreatment
(Parker, 2004). The National Institute for Health and Clinical
Excellence recommends that men are monitored under the START
(Study of Active Surveillance versus Radical Treatement in Patients
with Favourable-Risk Prostate Cancer) trial protocol, an ongoing
trial where men have their PSA level measured regularly, and
undergo prostate biopsy every 2 years (http://www.cancer.gov/
clinicaltrials/CAN-NCIC-CTG-PR11). Changes in PSA level, PSA
kinetics, are monitored regularly and clinical re-investigation is
undertaken if they suggest disease progression. However, this
recommendation is also based on expert opinion as two recent
systematic reviews showed no universally accepted method of
measuring or interpreting PSA level kinetics (Martin et al, 2006;
van den Bergh et al, 2008), and no firm evidence to support any of
the wide range of criteria currently being applied in the monitoring
programmes.
In this study, two measures of kinetics, PSA doubling time and
PSA velocity, and a novel reference range method (Bosch et al, 2006)
are applied to the PSA measurements taken from a cohort of men
who have been managed by monitoring for an average of 2.9 years,
allowing us to compare when the different methods raise alerts as
monitoring proceeds. Although data on clinical outcomes are not yet
available from this or other cohorts of men with screen-detected
prostate cancer, this analysis provides important early information
on how different approaches to monitoring behave in practice, thus
informing the choice of approach for full-scale evaluation.
PATIENTS AND METHODS
Patients
The study cohort included 408 men aged 45–70 years diagnosed
with histologically proven and clinically localised prostate cancer.
Between 2000 and 2008 these men had been invited to undergo a
PSA test as part of the UK-based ProtecT (Prostate testing for
cancer and Treatment) study (Donovan et al, 2003), and then
referred for biopsy due to a PSA level of 3.0ngml
–1or more. This
observational study cohort only includes men with clinically
localised prostate cancer who refused to be randomly allocated to a
treatment in the ProtecT trial, and then chose to be managed by
monitoring. The Trent multicentre research ethics committee
approved the study, and all participants provided informed
consent.
Each man had at least three PSA tests available, including two
obtained at diagnosis. At the outset, their mean age was 62 years
(s.d. 5.1 years; 90% range 53–69 years) and mean PSA level was
5.60ngml
–1(s.d. 2.78ngml
–1; 90% range 3.0–10.9ngml
–1). In all,
333 (82%) men had a Gleason score of p6, 73 men a score of 7 and
2 men had a score of 8. The mean duration of monitoring was 2.9
years (s.d. 1.8 years; 90% range 0.7–6.3 years) with PSA being
measured an average of 10.0 times (s.d. 5.0 times; 90% range 3–20
times). All men, whether randomly allocated to, or choosing
monitoring, are managed according to the same study protocol.
In brief, each patient was encouraged to undergo PSA tests every
3 months in year 1, and every 6 months thereafter. Re-biopsy was
not routine.
Methods of measuring PSA change
The PSA doubling-time method uses the rate of increase in PSA
measured on a natural logarithmic scale to predict the period of
time over which PSA will have doubled, with a short predicted
period raising concern. Following the literature, a regression
method is used to estimate PSA doubling time. This requires each
man to have had his PSA level tested on three or more occasions
(Martin et al, 2006; van den Bergh et al, 2008). A man’s log PSA
levels are regressed on the dates of measurement:
lnðPSAÞ¼a þ b time
where a and b are respectively the estimated intercept and gradient
of the regression line. A man’s PSA doubling time is then
calculated as ln(2)/b. Each time a new PSA measurement is taken,
the doubling time can be recalculated using the new measurement
and all measurements collected previously. Concern over the
reliability of estimates based on a handful of PSA measures has
been expressed, but this has been addressed by considering only
those doubling times calculated once the first five measures are
available (Ross et al, 2004; van den Bergh et al, 2007). An
alternative approach also requires five measurements to have been
taken, but is additionally focused on recent changes in a man’s
PSA level by using just the most recent five measurements (Ross
et al, 2004; van den Bergh et al, 2007).
In the present implementation of PSA velocity, all the PSA
measurements available for a man at a given point are regressed on
the measurement times:
PSA ¼ a þ b
0 time
where a and b0 are respectively the estimated intercept and gradient
of the regression line. The gradient b0 is taken as the measure of PSA
velocity in ngml
–1 per unit time. Again, this method can be
reapplied each time a new PSA measurement is taken.
Longitudinal reference ranges
Following the research done in other areas of medicine (Tilling,
Sterne, and Wolfe, 2001), longitudinal reference ranges have been
developed as an alternative to the above methods (Bosch et al,
2006; Tilling et al, 2009). Parameter values were estimated during a
multilevel model analysis of data from the Krimpen (the Nether-
lands) community-based study of normal age-related changes in
PSA levels (Bosch et al, 1995). The Krimpen study men were
comparable to those in the current cohort, being recruited from all
men residing in a defined area, aged 50–75 years at enrolment, and
being of predominantly northern European ancestry (Bosch et al,
1995). The model parameters are used to produce reference ranges
for each man’s subsequent period of monitoring, his age and initial
PSA level being taken into account (Bosch et al, 2006). Figure 1
shows the series of PSA measurements taken for an individual man
in the cohort alongside three reference ranges. From the top, these
are the reference ranges above which 5, 10 and 20% of men with
similar starting PSA levels will fall due to age-related changes in
PSA level. Hence, when the man falls above the 10% reference
range at 14 months, this suggests that his PSA level has increased
at a rate matched or exceeded by only one in ten healthy men. It is
postulated that this method may better accommodate the age-
related increases in PSA level that occur independently of prostate
cancer and thus distinguish deviations from the usual pattern in
men with cancer. For this study, longitudinal reference ranges
are calculated for each man, based on the man’s first two PSA
measurements and his age at the start of monitoring. A man is
alerted for further investigations when his latest PSA measurement
falls above a chosen reference for his current age.
Statistical methods
A Stata 10 (StataCorp 2007, College Station, TX, USA) batch file
was written to apply, retrospectively, each method to each man in
the cohort as each new measurement became available, with the
occurrence of alerts under the chosen thresholds being recorded.
For the purposes of this study, we retrospectively applied the
thresholds suggested by Klotz, which gave alerts when the
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sdoubling time was calculated to be o2 years and when the PSA
velocity was calculated to be 42ngml
–1 per year (Klotz, 2007).
Retrospectively applying the reference range method, we con-
sidered an alert to have resulted when the man fell into the highest
10% of PSA increases expected from age-related changes in PSA
level. This latter threshold is arbitrary, but, for the purposes of this
study, it gives an overall alert rate that is comparable to that of the
other methods.
RESULTS
Over the study period, 34% of men (n¼139) were alerted at least
once due to a simple PSA doubling time of o2 years, and 36% of
men (n¼148) were alerted at least once due to a PSA velocity of
42ngml
–1 per year. When doubling time was calculated using
just the five most recent measurements, 36% of men (n¼146)
were alerted. The reference range method alerted 34% of men
(n¼140), as on at least one occasion their PSA increase fell into
the top 10% of age-related increases for similar men.
Table 1 presents, for each method, the PSA measurements at
which alerts occur. The order rather than the timing of
measurements is given, and all alerts are included in the table
with some men subjected to multiple alerts. The PSA velocity and
doubling-time (all measurements) methods both alerted a high
proportion of men early on, but a rapidly diminishing proportion
as PSA measurements accumulated. Calculating the doubling-time
method only when at least five measurements of PSA are available
for a man avoids the high initial alert rate but does not avoid
the downturn in responsiveness. In contrast, doubling time
calculated using the five most recent measures alerts around
15% of men early on, followed by a much shallower decline in
responsiveness until around 8% of men are being alerted once a
man has accumulated more than ten measurements. No decline
in responsiveness is apparent for the reference range method,
roughly 8–10% of men being alerted at each measurement. The
contrast between the maintained responsiveness of the reference
range method and the declining responsiveness of the doubling-
time and velocity methods is particularly apparent in Figure 2.
The NICE guidance recommends that men with a doubling
time of o3 years should be alerted to the need for clinical review
(National Institute for Health and Clinical Excellence, 2008).
Applying this criterion to the present cohort leads to about half of
men being alerted at least once during the observation period, 49%
if doubling time is calculated from all available PSA measurements
Table 1 Number of alerts occurring with PSA velocity, doubling time applied to all data (DT all), doubling time applied to the most recent five measures
(DT 5), and the reference range method as additional tests become available
PSA test
PSA velocity 42ngml
–1
per year (%)
DT all
o24 months (%)
DT 5
o24 months (%)
Reference range
in top 10% (%)
Number
tested
1 — — — — 408
2 — — — 22 (5) 408
3 105 (26) 101 (25) — 33 (8) 408
4 76 (20) 71 (19) — 19 (5) 382
5 64 (18) 55 (15) 55 (15) 31 (9) 364
6 48 (15) 33 (10) 43 (13) 31 (10) 325
7 39 (14) 22 (8) 42 (15) 31 (11) 288
8 26 (10) 7 (3) 38 (15) 35 (14) 255
9 22 (10) 7 (3) 18 (8) 24 (11) 215
10 17 (9) 7 (4) 15 (8) 21 (11) 186
11 10 (6) 1 (1) 14 (8) 15 (9) 166
12 8 (5) 2 (1) 7 (5) 15 (10) 146
13 7 (6) 3 (2) 11 (9) 20 (16) 125
14 3 (3) 0 8 (8) 10 (10) 104
15 1 (1) 0 4 (5) 5 (7) 75
16+ 10 0 21 26 239
Men may be alerted more than once. Dashes indicate the early PSA tests at which a method cannot indicate an alert.
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Figure 2 Proportion of men alerted at each measurement occasion by a
doubling time, calculated from all data, of o2 years (dashed line), a
doubling time, calculated from the five most recent measurements, of o2
years (dotted line), a velocity of more than 2ngml
–1 per year (dot and
dash line), and due to exceeding the top 10% reference range (solid line).
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Figure 1 Reference ranges for an individual man, based on age-related
changes in a healthy man of the same age and starting PSA level. Plus signs
indicate individual measurements of the man’s PSA level during monitoring.
From the top, the three reference ranges distinguish the PSA level above
which the fastest increasing 5, 10 and 20% of similar healthy men will fall
due to age-related changes.
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sand 53% if calculated from the five most recent measurements. As
PSA measurements accumulate, adoption of the 3-year criterion
does not alter the decrease in responsiveness of the doubling time
calculated from all available measurements (25% of men alerted
after five measurements, 9% after ten measurements and 3% after
fifteen measurements), and the same largely maintained respon-
siveness is seen with doubling time calculated from the most recent
five measurements (21% of men alerted after ten measurements
and 20% after fifteen measurements).
Figure 3 again presents the series of PSA measurements
from our exemplar man, this time with all the investigated
methods applied. The two regression lines used in calculating
doubling time and the two regression lines used in calculating
velocity at the sixth and eleventh measurements are shown.
Measurements at which a method applied with the chosen
threshold causes an alert are shown as dots, other measurements
are shown as plus signs. The doubling-time method applied to
all measurements and PSA velocity alert the man repeatedly early
on, but not at all after 2 years of monitoring. Allowing the
doubling-time method to cause an alert only once five measure-
ment are available would have alerted the man at his fifth and
sixth measurements only, although the doubling-time method
applied to just the most recent five measurements would have
alerted the man at his fifth measurement only. The man also
exceeds his 10% upper reference range at his third and fifth
measurements and, in contrast to the doubling-time and velocity
methods, he continues to exceed it during his third and fourth
years of monitoring.
DISCUSSION
We have compared measures of PSA kinetics to a novel
longitudinal reference range approach, examining when these
different methods alert men whose localised prostate cancer is
being monitored. Prostate-specific antigen doubling time and PSA
velocity alert a high proportion of men initially but quickly
become unlikely to alert men as the PSA measurements
accumulate. In contrast, the reference range method appeared
equally sensitive to changes in PSA level as monitoring progressed.
Prostate-specific antigen doubling time and PSA velocity are
calculated by regressing a man’s series of PSA levels on the dates of
measurement. Early on, the calculations will be unreliable as they
will be overly susceptible to the well-known short-term variation in
PSA level. That unreliability is likely to be behind the initial high
rate of alerts with the regression-based methods. Once a man has
accumulated a number of measurements, regression will provide a
better indication of the overall trend in his PSA level, but will
become increasingly insensitive to any upturn in PSA level. This
problem has been described in a study of PSA velocity measured
using pre-operative PSA measurements (Yu et al, 2006). We
observed that the problem of increasing insensitivity was partly
avoided by using recent PSA measurements in the calculation of
doubling time (Yu et al, 2006), although this may allow too much
influence to short-term variations in the PSA level. Fundamentally,
the best-fit regression line for a series of PSA measurements will
be influenced by the balance of measurements taken during the
periods of steady PSA level and any subsequent upturn.
Consequently regression-based methods will be slow to highlight
changes in PSA level when used in long-term surveillance
programmes, with this insensitivity being resistant to minor
modifications to the method.
Prostate-specific antigen doubling time and PSA velocity alerted
around 35% of men at least once during an average of 2.9 years of
monitoring, comparable to the 39% of men alerted by a doubling
time of o2 years and the 49% of men alerted by a velocity of more
than 2ngml
–1 per year recently reported for the Sunnybrook
cohort after an average of 7 years monitoring (Klotz, 2007). The
Sunnybrook cohort includes men in their 70s and 80s, and with a
median age of 70, that cohort is older than the one examined in
this study. The two cohorts are comparable in having around 80%
of men with Gleason tumor grade of p6. With a much longer
average period of monitoring, a greater proportion of men might
have been expected to have been alerted in the Sunnybrook cohort,
but this does not seem to be the case for doubling time in
particular (Klotz, 2007). Either the same men are being alerted
repeatedly as monitoring proceeds, or doubling time is showing
the same insensitivity in the Sunnybrook cohort, alerting very few
men as measures accumulate.
Prostate-specific antigen doubling time and PSA velocity both
require the use of statistical software each time a new measure-
ment of PSA becomes available, and this may be difficult to achieve
in outpatient clinics (Schro ¨der, de Vries, and Bangma, 2003).
Although there are calculation tools for those methods on the
internet (Martin et al, 2006; van den Bergh et al, 2008), the
reference range approach is even more convenient in requiring
computer software only at the point when the first two measure-
ments of PSA are available. The longitudinal reference ranges can
then be plotted for an individual patient, and subsequent measures
of PSA compared with them. This method of monitoring PSA
levels over time seemed to remain sensitive to changes for the
whole period observed in this study. Furthermore, plotting a
reference range over time, as in Figure 1, shows the increase in PSA
level expected with advancing age in a healthy man. This may
provide reassurance, as what might be a worrying trend upwards is
shown to be consistent with the expected age-related increases for
a healthy man of similar age and starting PSA level (Latini et al,
2007; Pickles et al, 2007).
The short follow-up and the lack of clinical progression data are
the limitations of this study, as clinically relevant thresholds
cannot be determined and the sensitivity and specificity cannot be
compared between methods. There are currently no published data
available with both longitudinal PSA measurements and progres-
sion in untreated men with screen-detected localised prostate
cancer. The required data are accumulating in a number of studies
around the world, notably one North American (Klotz, 2007) and
three European studies (Donovan et al, 2003; Hardie et al, 2005;
van den Bergh et al, 2007), but it will be a number of years yet
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Figure 3 Prostate-specific antigen levels over time for an example case
managed by monitoring. Solid circles indicate measurements at which the
applied criterion caused an alert, plus symbols indicating the other
measurements. Solid lines indicate the regression lines fitted to calculate
doubling time (DT) and velocity at the sixth and eleventh measurements.
The dotted line is the longitudinal reference range threshold above which
10% of similar men are predicted to fall at each measurement time.
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sbefore these studies are able to report clinical outcome informa-
tion. Even then, it may be found that many cohort members have
switched to radical treatment without firm evidence of progressing
disease, as occurred in previous studies of monitoring in men with
clinically detected disease (Martin et al, 2006). In this context, this
study represents valuable preliminary work, indicating important
problems with currently promoted PSA-based criteria, which need
to be addressed now for men whose prostate cancer is currently
being managed by monitoring (Donovan et al, 2003; Hardie et al,
2005; Klotz, 2007; van den Bergh et al, 2007).
Selection bias is a further potential limitation, as a declining
alert rate in men monitored for long periods may be expected if
men alerted early are then treated radically and thus removed from
our cohort. In other words, those men still being managed by
monitoring after seven or eight PSA measurements may be a
selected group with very stable PSA levels. This is unlikely to be a
full explanation of our findings, as the reference range method is
detecting a similar proportion of men with increasing PSA levels
over the whole observation period.
In conclusion, there is little research evidence to guide the use of
PSA kinetics for monitoring men with screen-detected and
localised prostate cancer, and this study highlights problems with
the methods currently recommended by NICE. Prostate-specific
antigen doubling time and PSA velocity seem to rapidly become
insensitive to changes as a man undergoes repeated tests, and this
may mean they are unsuitable for the long-term monitoring/
surveillance of men with localised prostate cancer. There is now a
need for novel methods of monitoring, such as the reference range
method evaluated here, which should be evaluated in ongoing
studies of monitoring for validation against clinical progression
events and disease outcome. The NICE guidance needs to make
men and clinicians, using methods of surveillance/monitoring for
prostate cancer, aware of the uncertainties about PSA kinetics and
of the caution required in interpreting PSA changes.
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